A Phase I, Randomized, Double-Blind, Placebo-Controlled, Escalating Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus

Trial Profile

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Escalating Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2014

At a glance

  • Drugs Rontalizumab (Primary) ; Rontalizumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Oct 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top